Pharmacology of valsartan, an angiotensin II receptor antagonist

Bibliography

• BROWN NJ, VAUGHAN DE: Angiotensin-converting en-zyme inhibitors. Circulation (1998) 97:1411–1420.
   PubMed Web of Science ®Google Scholar
• WAEBER B, NUSSBERGER J, BRUNNER HR: Angiotensin-converting enzyme inhibitors in hypertension. In: Hy-pertension: Pathophysiology, Diagnosis and Management (2nd Edition). Laragh JH, Brenner BM (Eds.), Raven Press, New York (1995):2861–2872.
   Google Scholar
• PFEFFER MA, BRAUWALD MD, MOYE LA et al.: Effect of captopril on mortality and morbidity in patients with ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. New Engl. J. Med. (1992) 327:669–677.
   PubMed Web of Science ®Google Scholar
• THE SOLVD INVESTIGATORS: Effect of enalapril on mortality and the development of heart failure in as-ymptomatic patients with reduced left ventricular ejection fraction. New Engl. J. Med. (1992) 327:685–691.
   PubMed Web of Science ®Google Scholar
• LEWIS EJ, HUNSICKER LG, BAIN RP et al.: The effect of angiotensin-converting-enzyme inhibition on dia-betic nephropathy. New Engl. J. Med. (1993) 329:1456–1462.
   PubMed Web of Science ®Google Scholar
• SUSIC D, FROHLICH ED: Nephroprotective effect of an-tihypertensive drugs in essential hypertension. J. Hy-pertens. (1998) 16:555–567.
   Google Scholar
• ISRAILI ZH, HALL WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme in-hibitor therapy. A review of the literature and patho-physiology. Ann. Intern. Med. (1992) 117:234–242.
   PubMed Web of Science ®Google Scholar
• MESSERLI FH, WEBER MA, BRUNNER HR: Angiotensin re-ceptor inhibition. A new therapeutic principle. Arch. Intern. Med. (1996) 156:1957–1965.
   PubMed Web of Science ®Google Scholar
• JOHNSTON CI: Angiotensin receptor antagonist: focus on losartan. Lancet (1995) 346:1403–1407.
   PubMed Web of Science ®Google Scholar
• CRISCIONE L, DE GASPARO M, BUHLMAYER P etal: Phar-macological profile of valsartan: a potent, orally ac-tive, non-peptide antagonist of the angiotensin II ATi-receptor subtype. Br. J. Pharmacol (1993) 110:761–771.
   PubMed Web of Science ®Google Scholar
• DE GASPARO M, WHITEBREAD S: Binding of valsartan to mammalian angiotensin ATi receptors. Regul. Peptides (1995) 59:303–311.
   PubMed Web of Science ®Google Scholar
• HAYASHI N, YAMAMOTO S, KOMETANI M etal: Pharma-cological profile of valsartan, a non-peptide angio-tensin II type 1 receptor profile. 3rd commnunication: haemodynamic effects in rats and dogs. Arzneim.-Forsch./Drug Res. (1997) 47:620–625
   Google Scholar
• WEBB RL, NAVARRETE AE, DAVIS S: Effects of valsartan and hydrochlorothiazide alone or in combination on blood pressure and heart rate in conscious-telemetered spontaneously hypertensive rats. Am. J. Hypertens. (1998) 11:59–65
   PubMed Web of Science ®Google Scholar
• YAMAMOTO S, HAYASHI N, KOMETANI M et al.: Pharma-cological profile of valsartan, a non-peptide angio-tensin II type 1 receptor profile. 1st communication: antihypertensive effects of valsartan in hypertensive models. Arzneim.-Forsch./Drug Res. (1997) 47:604–612.
   Google Scholar
• KOMETANI M, HAYASHI N, YAMAMOTO S etal: Pharma-cological profile of valsartan, a non-peptide angio-tensin II type 1 receptor profile. 2nd communication: valsartan prevents end-organ damage in spontane-ously hypertensive stroke prone rats during 1-year treatment. Arzneim.-Forsch./Drug Res. (1997) 47:613–619.
   Google Scholar
• HAYASHI N, FUJIMURA Y, YAMAMOTO S et al.: Pharma-cological profile of valsartan, a non-peptide angio-tensin II type 1 receptor profile. 4th communication: improvement of heart failure of rats with myocardial infarction by valsartan. Arzneim.-Forsch./Drug Res. (1997) 47:625–629.
   Google Scholar
• YAMAMOTO S, HAYASHI N, KOMETANI M etal: Pharma-cological profile of valsartan, a non-peptide angio-tensin II type 1 receptor profile. 5th communication: haemodynamic effects of valsartan in dog heart failure models. Arzneim.-Forsch./Drug Res. (1997) 47:630–634.
   Google Scholar
• SPINALE FG, DEGASPARO M, WHITEBREAD S et al.: Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. I. Effects on left ventricu-lar performance and neurohormonal systems. Circu-lation (1997) 96:2385–2396
   Google Scholar
• MACKENZIE H, OTS M, ZIAI F et al.: Angiotensin recep-tor antagonists in experimental models of chronic re-nal failure. Kidney Int. (1997) 63 (Suppl.) :S140–S143.
   Google Scholar
• ENDLICH K, STEINHAUSEN M: Role of kinins and angio-tensin II in the vasodilating action of angiotensin con-verting enzyme inhibition in rat renal vessels. J. Hypertens. (1997) 15:633–641.
   PubMed Web of Science ®Google Scholar
• KOMERS R, COOPER ME: Acute renal haemodynamic ef-fects of ACE inhibition in diabetic hyperfiltration: roles of kinins. Am. J. Physic)]. (1995) 268:F588–F594.
   Web of Science ®Google Scholar
• ALLEN TJ, CAO Z, YOUSSEF S, HULTHEN UL, COOPER ME: Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural stud-ies. Diabetes (1997) 46:1612–1618.
   Google Scholar
• REMUZZI A, FASSI A, SANGALLI F et al: Prevention of re-nal injury in diabetic MINE rats by angiotensin II an-tagonism. Exp. Nephrol. (1998) 6:28–38.
   PubMedGoogle Scholar
• WU LL, COX A, ROE CJ et al: Transforming growth fac-tor 01 and renal injury following subtotal nephrec-tomy in the rat: role of the renin-angiotensin system. Kidney Int. (1997) 51:1553–1567.
   PubMed Web of Science ®Google Scholar
• CHOW L, DE GASPARO M, LEVENS N: Improved glucose metabolism following blockade of angiotensin con-verting enzyme but not angiotensin ATI receptors. Eur. J. Pharmacol. (1995) 282:77–86.
   PubMed Web of Science ®Google Scholar
• FLESCH G, MULLER P, LLOYD P: Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur. J. Clin. Pharmacol. (1997) 52:115–120.
   PubMed Web of Science ®Google Scholar
• MULLER P, COHEN T, DE GASPARO M et al.: Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur. J. Clin. Pharmacol. (1994) 47:231–345.
   Google Scholar
• MULLER P, FLESCH G, DE GASPARO M et al.: Pharmacoki-netic and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, nor-motensive subjects. Eur. J. Clin. Pharmacol. (1997) 52:441–449.
   Google Scholar
• MORGAN JM, PALMISANO M, PIRAINO A et al.: The effectof valsartan on the angiotensin II pressor response in healthy normotensive male subjects. Clin. Pharmacol. Ther. (1997) 61:35–44.
   PubMed Web of Science ®Google Scholar
• BINDSCHEDLER M, DEGEN G, FLESCH M et al.: Pharma-cokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur. J. Clin. Pharmacol. (1997) 52:371–378.
   PubMed Web of Science ®Google Scholar
• COLUSSI DM, PARISOT C, ROSSOLINO ML et al: Proteinbinding of valsartan, a new angiotensin II receptor an-tagonist. J. Clin. Pharmacol (1997) 37:214–221.
   PubMed Web of Science ®Google Scholar
• WALDMEIER F, FLESH G, MULLER P et al.: Pharmacoki-netics, disposition and biotransformation of 14C-radiolabelled valsartan in healthy male volunteers af-ter a single oral dose. Xenobiotica (1997) 27:59–71.
   PubMed Web of Science ®Google Scholar
• CRISCIONE L, BRADLEY WA, BeHLMAYER P et al.: Valsar-tan: preclinical and clinical profile of an antihyperten-sive angiotensin-II antagonist. Cardiovasc. Drug Rev. (1995) 13(3):230–250.
   Google Scholar
• SIOUFI A, MARFIL F, JAOUEN A et al: The effects of ageon the pharmacokinetics of valsartan. Biopharm. Drug Dispos. (1998) 19:237–344.
   PubMed Web of Science ®Google Scholar
• BROOKMAN LJ, ROLAN PE, BENJAMIN IS et al.: Pharma-cokinetics of valsartan in patients with liver disease. Pharmacol. Ther. (1997) 62:272–278.
   Web of Science ®Google Scholar
• PERICO N, SPORMANN D, PERUZZI et al Efficacy and tolerability of valsartan compared with lisinopril in patients with hypertension and renal insufficiency. Clin. Drug. Invest. (1997) 14:252–259.
   Web of Science ®Google Scholar
• CZENDLIK CH, SIOUFI A, PREISWERK G et al.: Pharma-cokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol. Eur. J. Clin. Pharmacol (1997) 52:451–459.
   PubMed Web of Science ®Google Scholar
• SCHMIDTH EK, ANTONIN KH, FLESH G et al.: An interac-tion study with cimetidine and the new angiotensin II antagonist valsartan. Eur. J. Clin. Pharmacol. (1998) 53:451–458.
   PubMed Web of Science ®Google Scholar
• FUMERON C, SCHMITT F, BRILLET G eta].: Renal effect ofvalsartan and benazepril in healthy volunteers. 13th World Congress of Cardiology. Rio de Janeiro (1998). Ab-stract.
   Google Scholar
• FRICKER AF, NUSSBERGER J, MEILENBROCK S et al.: Ef-fect of indomethacin on the renal response to angio-tensin II receptor blockade in healthy subjects. Kidney Int. (1998). (In Press.)
   Google Scholar
• STRODTER D, ZEISSIG I, HEATH R et al.: Angiotensin-II antagonist CGP-48933 (valsartan): results of a double-blind, placebo controlled multicentre study. Nieren. Hoch. (1994) 23:217–220.
   Google Scholar
• CHRYSANT SG, HOLTZMAN J, LEWIN A et al.: Results of pilot dose-ranging trial of valsartan in patients with es-sential hypertension. Am. J. Hypertens. (1996) 9 (2) :121A. Abstract
   Google Scholar
• OPARIL S, DYKE S, HARRIS F et al.: The efficacy andsafety of valsartan compared with placebo in the treat-ment of essential hypertension. Clin. Ther. (1996) 18:797–810.
   PubMed Web of Science ®Google Scholar
• NEUTEL J, WEBER M, POOL J et al.: Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin. Ther. (1997) 19:447–458.
   PubMed Web of Science ®Google Scholar
• COREA L, CARDONI O, FOGARI R et al.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension. A comparative study of the efficacy and safety against amlodipine. Clin. Pharmacol. Ther. (1996) 60:341–346.
   Google Scholar
• HOLWERDA N, FOGARI R, ANGELI P et al.: Valsartan, anew angiotensin II antagonist for the treatment of es-sential hypertension: efficacy and safety compared with placebo and enalapril. j Hypertens. (1996) 14:1147–1151.
   PubMed Web of Science ®Google Scholar
• BLACK HR, GRAFF A, SHUTE R et al.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety com-pared to an angiotensin-converting enzyme inhibitor, lisinopril. J. Human Hypertens. (1997) 11:483–489.
   PubMed Web of Science ®Google Scholar
• HEGNER G, FAUST G, FREYTAG F et al.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydro-chlorothiazide. Eur. J. Clin. Pharmacol. (1997) 52:173–177.
   PubMed Web of Science ®Google Scholar
• BREMNER AD, BAUR M, ODDOU-STOCK P et al.: Valsar-tan: long term efficacy and tolerability compared to lisinopril in elderly patients with essential hyperten-sion. Clin. Exp. Hypertens. (1997) 19 (8) :1263–1285.
   PubMed Web of Science ®Google Scholar
• CIFKOVA R, PELESKA J, HRADEC J et al: Valsartan andatenolol in patients with severe primary hyperten-sion. J. Human Hypertens. (In Press.)
   Google Scholar
• ODDOU-STOCK P, GATLIN M, KOBI P et al.: Comparisonof the efficacy of two angiotensin II antagonists,valsar-tan and losartan, in essential hypertension. Am. J. Hy-pertens. (1997) 10 (4) :84A. Abstract
   Google Scholar
• RUILOPE LM, ALDIGIER JC, PONTICELLI C et al.: Safety of the combination of valsartan (V) and benazepril (BZ) in patients with chronic renal disease (CRD). JASN (1997) 8:75A.
   Google Scholar
• THeRMANN A, KENEDI P, SCHMIDT A et al: Influence of the angiotensin II antagonist valsartan on left ven-tricular hypertrophy in patients with essential hyper-tension. Circulation (In Press.)
   Google Scholar
• BARUCH L: The haemodynamic and hormonal effectsof ATi receptor blockade added to ace inhibition in heart failure. Am. J. Hypertens. (1998). Abstract.
   Google Scholar
• MAZAYEV VP, FOMINA IG, KAZAKOV EN eta].: Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int. J. Cardiol. (In Press.)
   Google Scholar
• BENZ J, OSHRAIN C, HENRY D et al.: Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisino-pril and hydrochlorothiazide. J. Clin. Pharmacol. (1997) 37:101–107.
   PubMed Web of Science ®Google Scholar